Premium
Successful use of once‐daily high‐dose darunavir and dolutegravir in multidrug‐resistant HIV
Author(s) -
Fulco Patricia P.,
Leibrand Kaczmar Crystal R.,
Gomes Denese,
Smith Tima
Publication year - 2020
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13081
Subject(s) - dolutegravir , darunavir , medicine , emtricitabine , dosing , ritonavir , regimen , tenofovir alafenamide , abacavir , pharmacology , human immunodeficiency virus (hiv) , virology , viral load , antiretroviral therapy
What is known and objective? Antiretroviral (ARV) resistance may result during periods of consistently poor adherence. We report the successful use of a novel once‐daily (QD) ARV regimen in a patient with multidrug‐resistant (MDR) HIV. Case summary Once‐daily darunavir 1200 mg/ritonavir 100 mg, dolutegravir and emtricitabine/tenofovir alafenamide was initiated with directly observed therapy. With the assistance of therapeutic drug monitoring, dolutegravir dosing was increased to 150 mg daily. The patient maintained virologic suppression for 18 months. What is new and conclusions? In this case, QD darunavir/ritonavir achieved similar trough concentrations to twice daily dosing with dolutegravir dose titration necessitated and resulted in HIV virologic control.